Human genetic variation, population pharmacokinetic - Dynamic models, Bayesian feedback control, and maximally precise individualized drug dosage regimens

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 4, 2009, Pages 249-262

  Jelliffe, R ^a   Schumitzky, A ^a,b   Bayard, D ^a,c   Leary, R ^a,d   Botnen, A ^a   Van Guilder, M ^a   Bustad, A ^a   Neely, M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d PHARSIGHT CORPORATION   (United States)

Author keywords

Genetic variability and drug dosage; Multiple model drug dosage; Optimal stochastic adaptive control; Population pharmacokinetic modeling; Therapeutic drug monitoring

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYTOCHROME P450 2D6; GENTAMICIN; METOPROLOL;

ACCURACY; AGE; ANALYTICAL ERROR; BAYES THEOREM; BODY WEIGHT; CIGARETTE SMOKING; COMPUTER PROGRAM; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG MONITORING; EXPERIMENTAL MODEL; FEEDBACK SYSTEM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HIGH THROUGHPUT SCREENING; HUMAN; INDIVIDUALIZATION; KIDNEY FUNCTION; MAXIMUM LIKELIHOOD METHOD; MONTE CARLO METHOD; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; PARAMETRIC TEST; PATIENT INFORMATION; PATIENT MONITORING; PHARMACOGENETICS; PHARMACOGENOMICS; POPULATION GENETICS; POPULATION RESEARCH; PROBABILITY; REVIEW; SEX DIFFERENCE; TRANSCRIPTOMICS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 73649092728     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569209790112382     Document Type: Review

References (50)

1. Kaila N, Straka R, Brundage R. Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokin Pharmacodyn 2007; 34: 141-56.
2. Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-7.
3. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of 'edge effect' and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13(1): 43-62.
4. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10): 665-74.
5. Yen-Revollo JL, Auman JT, McLeod HL. Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics 2008; 9(11): 1639-45.
6. Ozdemir V, Graham JE, Godard B. Race as a variable in pharmacogenomics science: From empirical ethics to publication standards. Pharmacogenet Genomics 2008; 18(10): 837-41.
7. Teorell T. Kinetics of distribution of substances administered to the body. (I). The Extravascular Modes of Administration. Arch Int Pharmacodyn Ther 1937; 57: 205-25.
8. Teorell T. Kinetics of distribution of substances administered to the body. (II). The Intravascular Modes of Administration. Arch Int Pharmacodyn Ther 1937; 57: 226-40.
9. Sawchuk R, Zaske D, Cipolle R, et al. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362-69.
10. Jelliffe R, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380-93.
11. Sheiner L, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305.
12. Beal S, Sheiner L. NONMEM User's Guide. (I). Division of Clinical Pharmacology, University of California, San Francisco 1979.
13. Rowland M, Sheiner L, Steimer J-L, Eds. Variability in Drug Therapy: Description, Estimation, and Control. New York: Raven Press 1985.
14. Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol 2009; 65(7): 667-78.
15. Bertrand J, Comets E, Laffont CM, et al. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn 2009; 36(4): 317-39.
16. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009; 85(5): 485-94.
17. Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical data set and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365-83.
18. Bauer J, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9(1): E60-83.
19. Bauer R, Guzy S, Ng C. A comparison of estimation methods in nonlinear mixed-effect models for population pharmacokinetic - pharmacodynamic analysis. Full report presented at the European Population Approach Group Meeting, Marseille, France. June 18-20, 2008.
20. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73: 645-56.
21. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. Appl Math Computat 1991; 45: 143-57.
22. Leary R, Jelliffe R, Schumitzky A, et al. Nonparametric pharmacokinetic/dynamic population modeling with adaptive grids. Full report presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, USA. March 6-10, 2001.
23. Lindsay B. The geometry of mixture likelihoods: A general theory. Ann Statistics 1983; 11: 86-94.
24. Roberts AW, Varberg D. Convex Functions. New York: Academic Press 1973; pp.76.
25. Kiefer J, Wolfowitz J. Consistency of the maximum likelihood estimator in the presence of infinitely many nuisance parameters. Ann Math Stat 1956; 27: 887-906.
26. Bulitta JB, Landersdorfer CB, Schumitzky A, et al. Comparison of bias and precision of nonparametric and parametric population methods assessed via nonparametric bootstrap methods in NPAG and NONMEM. Full report presented at the American Conference on Pharmacometrics (ACoP), Tucson, Arizona, USA. March 9-12, 2008.
27. D'Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739-56.
28. Jelliffe R, Gomis P, Schumitzky A. A population model of gentamicin made with a new nonparametric EM algorithm. Technical Report 90-4, Laboratory of Applied Pharmacokinetics, USC School of Medicine, Los Angeles, CA, USA 1990.
29. Antic J, Laffont C, Chafai D, et al. Comparison of nonparametric methods in nonlinear mixed effects models. Comput Stat Data Anal 2009; 53: 642-56.
30. nd ed., Reading, MA: Addison-Wesley 1989; pp. 420-24.
31. Jelliffe R, Jelliffe S. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight. Math Biosci 1972; 4: 17-24.
32. Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol 2002; 22: 320-4.
33. Wheeler L, Sheiner L. Clinical estimation of creatinine clearance. Am J Clin Pathol 1979; 72: 27-31.
34. Chiou W, Hsu F. A new simple and rapid method to monitor the renal function based on pharmacokinetic consideration of endogenous creatinine. Res Commun Chem Pathol Pharmacol 1975; 10: 316-30.
35. Brater D. Drug use in renal disease. Balgowlah, Australia: ADIS Health Science Press 1983; p. 29.
36. Jelliffe R, Bayard D, Schumitzky A, et al. The multiple model method of maximally precise individualized dosage regimens. Full report presented at the MM-USCPACK Clinical Collection of Computer Programs, Pharmacokinetics Section, XI Annual Meeting of "Chelovek i Lekarstvo" (Man and Drugs), Moscow, Russia. April 20, 2004.
37. Jelliffe R, Bayard D, Schumitzky A, et al. Multiple Model (MM) dosage design: Achieving target goals with maximal precision. Full report presented at the 14th IEEE Symposium on Computer-Based Medical Systems (CMBS'01), Bethesda, MD, USA. July 26-27, 2001.
38. Jelliffe R, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualized drug therapy: linkage of population modeling, new "multiple model" dosage design, Bayesian feedback, and individualized target goals. Clin Pharmacokinet 1998; 34: 57-77.
39. Bayard D, Jelliffe R, Schumitzky A, et al. Precision drug dosage regimens using multiple model adaptive control: Theory and application to simulated vancomycin therapy. In: Sridhar R, Rao KS, Lakshminarayanan V, Eds. Selected topics in Mathematical Physics. R. Vasudevan Memorial volume, Madras: World Scientific Publishing Co. 1995.
40. Bayard D, Jelliffe R. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn 2004; 31: 75-107.
41. Macdonald I, Staatz C, Jelliffe R, et al. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit 2008; 30: 67-74.
42. Proost JH, Meijer DKF. PW-Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-63.
43. Therapeutic Drug Monitoring System. Healthware, Inc., San Diego CA 2000.
44. Mungall D, Heissler J. Computer approaches in clinical pharmacokinetics and pharmacodynamics. In: Derendorf H, Hochhaus G, Eds. Handbook of Pharmacokinetic and Pharmacodynamic Correlations. Boca Raton, Florida: CRC Press 1995; pp. 415-63.
45. Jelliffe R, Schumitzky A, Van Guilder M, et al. User Manual for Version 10.7 of the USC*PACK Collection of PC Programs, USC Laboratory of Applied Pharmacokinetics, December 1, 1995.
46. Jelliffe R, Buell J, Kalaba R. Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. In: Reggia J, Tuhrim S, Eds. Computer-Assisted Medical Decision Making. New York: Springer-Verlag 1985; vol. 1: pp. 93-124.
47. Rodman J, Jelliffe R, Kolb E, et al. Clinical studies with computer-assisted initial lidocaine therapy. Arch Int Med 1984; 144: 703-9.
48. van Lent-Evers N, Mathot R, Geus W, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63-73.
49. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of pediatric marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28: 743-51.
50. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 2008; 48: 1081-91.